This Article  • Full text  • PDF  • Correction  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Arrhythmias  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Peter J. Zimetbaum, MD, Discussant

JAMA. 2007;297:1909-1916.

Nearly 450 000 individuals experience sudden cardiac death yearly in the United States. A history of prior myocardial infarction with resultant left ventricular dysfunction identifies a group at particularly high risk of sudden arrhythmic death. Implantable cardioverter-defibrillators have proven highly effective at reducing this risk and are now increasingly implanted in patients with this risk profile. The case of Mr M, a 59-year-old man with a history of myocardial infarction, low ejection fraction, and mild congestive heart failure, who is considering implantable cardioverter-defibrillator placement, illustrates the issues in having a device implanted as a prophylactic measure as well as increasing concerns due to device recalls and malfunction. A thorough discussion of the benefits and risks associated with this therapy is necessary for patients and physicians to make appropriate decisions with regard to the primary prevention of sudden death.

Author Affiliation: Dr Zimetbaum is Associate Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.

RELATED ARTICLE

Implantable Cardioverter-Defibrillators
Janet M. Torpy, Cassio Lynm, and Richard M. Glass
JAMA. 2007;297(17):1946.
EXTRACT | FULL TEXT